AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for June 24, 2015 meeting

IV. Secretary’s report

V. Old Business
   A. HMO responses to DURB follow-up questions
   B. Currently available direct-acting antiviral Hepatitis C drugs by genotype (updated August 2015)

VI. New Business
   A. Proposed protocols
      1. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors
      2. Daclatasvir (Daklinza®)
      3. Ombitasvir, paritaprevir and ritonavir (Technivie®)
   B. NJ Drug Utilization Review Board Annual Report for SFY 2015 (for Board Members review only)

VII. Informational Highlights/Reports
    2. Summary of DURB Action Items
    3. DHS and DHSS Programs Top Drugs Report (by amount paid and by category)
    4. Medication information:
       (a) FDA approves first treatment for sexual desire disorder
       (b) FDA Approves Use Of Opioid Pain Treatment For Some Youngsters
       (c) Number Of Marijuana Dispensaries Correlated With Abuse, Study Finds
       (d) HIV May Continue To Multiply In Patients Who Are Responding Well To Antiretroviral Therapy